I’m a disabled American. Trump’s policies will be a disaster for people like me.
By Ari Ne'eman,
Vox
| 11. 09. 2016
It’s the early hours of Wednesday morning, and I’m watching my friends fear for their lives on Twitter. We’ve just learned that Donald J. Trump will be the next president of the United States. People are talking about the likelihood that they’ll lose health insurance when the Affordable Care Act is repealed, the fear that the attendant who helps them get dressed in the morning will no longer be available when Medicaid is slashed, the possibility that their conversations with their therapist may no longer be private, the impossibility of paying out of pocket for the medications, in-home care, assistive technology, and other essential parts of disabled life. Like many other people with disabilities, we’re terrified by the prospect of a Trump administration and what it may bring to people like us.
Much has been made over (now President-elect) Donald Trump’s mocking of disabled New York Times reporter Serge Kovaleski last year. Spurred by the widespread outrage at Trump’s cruelty, the Democratic National Committee made disability rights a high-profile theme of its 2016 convention. But for most disability...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...